Detection of mutant p53 protein in workers occupationally exposed to benzidine

Journal of Occupational Health

Volumn 49, Issue 4, 2007, Pages 279-284

  Xiang, Cui Qin ^a,b   Shen, Chun Lin ^a   Wu, Zi Rong ^a   Qin, Yi Qiu ^a   Zhang, Yun Ying ^a   Liu, Cha Zhen ^a   Chen, Ji Gang ^a   Zhang, Sheng Nian ^a  

^a EAST CHINA NORMAL UNIVERSITY   (China)

^b SHANGHAI MUNICIPAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Benzidine; Exfoliated urothelial cells; Exposure intensity index; Mutant p53 protein; Papanicoloau's grading

Indexed keywords

BENZIDINE; BENZIDINE DERIVATIVE; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER TUMOR; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; GENETICS; HUMAN; MALE; MIDDLE AGED; MUTATION; OCCUPATIONAL DISEASE; OCCUPATIONAL EXPOSURE; PATHOLOGY; POLYMERASE CHAIN REACTION; UROTHELIUM;

ADULT; AGED; AGED, 80 AND OVER; BENZIDINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MIDDLE AGED; MUTATION; OCCUPATIONAL DISEASES; OCCUPATIONAL EXPOSURE; POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 35148886245     PISSN: 13419145     EISSN: 13489585     Source Type: Journal    
DOI: 10.1539/joh.49.279     Document Type: Article

References (27)

1. IARC. Bnzidine. IARC Monographs, Supple 17. Lyon: IARC, 1987: 123
2. Chen JG: Surveillance on bladder cancer in the population of exposure to benzidine in Shanghai. China Tumor 10, 206-208 (2001) (in Chinese)
3. Hayes RB, Bi W, Rothman N, Broly F, Caporaso N, Feng P, You X, Yin S, Woosley RL and Meyer UA: N-Acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers. Carcinogenesis 14, 675-678 (1993)
4. Bi W, Hayes RB, Feng P, Qi Y, You X, Zhen J, Zhang M, Qu B, Fu Z, Chen M, CoChient HT and Blot WJ: Mortality and incidence of bladder cancer in benzidine-exposed workers in China. Am J Ind Med 21, 481-489 (1992)
5. Wu ZR, Chen FD, Qi BJ, Qian M and Wang LF: Development and application of a universal immuno-PCR system. Chin J Med Lab Sci 20, 147-149 (1997) (in Chinese)
6. Wu ZR, Chen FD, Qian M, Qi BJ and Wang LF: Development and application studies of a new immuno-PCR system. Biotechnology 7, 9-11 (1997)
7. Qiao SJ, Wu ZR, Qi BJ and Wang LF: Construction of a new immuno-PCR gene probe and primary diagnostic study. Science in China 28, 77-82 (1998) (in Chinese)
8. Zhang MH, Wang XY, Wu ZR, Zhu XM and Song PJ: Primary study on immuno-PCR fordetection of mutant p53 protein in cancer. Biotechnology 10, 9-11 (2000)
9. Sano T, Smith CL and Cantor CR: Immuno-PCR: very sensitive antigen detection by means of specific antibody-DNA conjugates. Science 258, 120-122 (1992)
10. Zhou HR, Fisher J and Papas TS: Universal immuno-PCR for ultra-sensitive target protein detection. Nucleic Acids Res 21, 6038-6039 (1993)
11. Hendrickson ER, Truby TM, Joerger RD, Majarian WR and Ebersole RC: High sensitive multianalyte immunoassay using covalent DNA-labelled antibodies and polymerase chain reaction. Nucleic Acids Res 23, 522-529 (1995)
12. Wei X, Xiang CQ, Gu ZW, Xu B, Dong HM and Wu ZR: Application studies of p53 protein on the surveillance of tumor high-risk population in rubber industry. Chin J Ind Hyg Occup Dis 17, 168-169 (1999) (in Chinese)
13. Papanicolaou GN: A new procedure for staining vaginal smears. Science 95, 438-439 (1942)
14. Papanicolaou GN and Marshall VF: Urine sediment smears: a diagnostic procedure in cancer of the urinary tract. Science 101, 519-520 (1945)
15. He DL and He HQ: Oncology of male urogenital system. Science & Technology Press of Shanxi, 173 (1999) (in Chinese)
16. Institute of Oncology, Chinese Academy of Medical Science: Clinical cytological atlas of tumour. People's Press of Hygiene, 166-172 (1984) (in Chinese)
17. Houghton A, Oyajobi BO, Foster GA, Russell RGGc and Stringer BMJ: Immortalization of human marrow stromal cells by retroviral transduction with a temperature sensitive oncogene: indentification of bipotential precursor cells capable of directed differentiation to either an osteoblast or adipocyte phenotype. Bone 22, 7-16 (1998)
18. Lanni JS and Jacks T: Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol Cell Biol 18, 1055-1064 (1998)
19. Uzoaru I, Rubenstein M, Mirochnik Y, Slobodskoy L, Shaw M and Guinan P: An evaluation of the markers p53 and Ki-67 for their predictive value in prostate cancer. J Surg Oncol 67, 33-37 (1998)
20. Martone T, Airoldi L, Magagnotti C, Coda R, Randone D, Malaveille C, Avanzi G, Merletti F, Hautefeuille A and Vineis P: 4-Aminobiphenyl-DNA adducts and p53 mutation in bladder cancer. Int J Cancer 75, 512-516 (1998)
21. Katabami M, Dosaka-Akita H, Honma K, Kimura K, Fujino M, Uchida Y, Mikami H, Ohsaki Y, Kawakami Y and Kikuchi K: p53 and Bcl-2 expression in pneumoconiosis-related pre-cancerous lesions and lung cancers: frequent and preferential p53 expression in pneumoconiotic bronchiolar dysplasias. Int J Cancer 75, 504-511 (1998)
22. Li YF and Qian GS: The structure, function and mechanism of p53 protein. Tumor 13, 40-41 (1993)
23. Lane DP: Cancer: a death in the life of p53. Nature 362, 786-787 (1993)
24. Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutation in the human cancers. Science 253, 49-53 (1991)
25. Chen PL, Chen YM, Bookstein R and Lee WH: Genetic mechanism of tumor suppression by the human p53 gene. Science 250, 1576-1580 (1990)
26. Sarkis AS, Dalbagni G and Gordon C: Nuclear overexpression of p53 protein in transitional cell bladder cancer carcinoma: a marker for disease progression. J Natl Cancer Inst 85, 53 (1993)
27. Yasunaga Y, Nakanishi H, Naka N, Miki T, Tsujimura T, Itatani H, Okuyama A and Aozasa K: Alteration of the p53 gene in occupational bladder cancer in workers exposed to aromatic amines. Lab Invest 77, 677-684 (1997)